Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formylmethionyl-leucyl-phenylalanine to neutrophil receptors.

Losartan, a selective antagonist of AT1 receptors for angiotensin II, is widely used clinically to manage hypertension. We report here that losartan markedly inhibits neutrophil shape change, adherence and chemiluminescence responses triggered by N-formylmethionyl-leucyl-phenylalanine (fMLP), without affecting responses induced by immune complexes, zymosan or concanavalin A. Neither saralasin, another antagonist of angiotensin II receptors, nor captopril, an angiotensin-converting enzyme inhibitor, reproduced the effects of losartan. It was also observed that neutrophil responses triggered by fMLP were not affected by exogenously added angiotensin II. The effect of losartan on the binding of fMLP was measured using [3H]fMLP. It was found that losartan inhibits the binding of [3H]fMLP to neutrophil receptors. As observed for neutrophils, studies performed with monocytes showed that losartan inhibits chemiluminescence emission triggered by fMLP, without affecting chemiluminescence responses triggered by immune complexes, zymosan or concanavalin A.

[1]  P. Corvol,et al.  Angiotensin II receptors: protein and gene structures, expression and potential pathological involvements. , 1996, European journal of endocrinology.

[2]  C. Johnston,et al.  Angiotensin receptor antagonists: focus on losartan , 1995, The Lancet.

[3]  C. Haslett,et al.  CD66‐dependent neutrophil activation: a possible mechanism for vascular selectin‐mediated regulation of neutrophil adhesion , 1995, Journal of leukocyte biology.

[4]  T. Kitazono,et al.  Evidence that angiotensin II is present in human monocytes. , 1995, Circulation.

[5]  G. Tsujimoto,et al.  Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leucocytes. , 1995, Endocrine journal.

[6]  D. Batlle,et al.  Selected Aspects of ACE Inhibitor Therapy for Patients with Renal Disease: Impact on Proteinuria, Lipids and Potassium , 1995, Journal of clinical pharmacology.

[7]  T. Resink,et al.  Activation of human peripheral monocytes by angiotensin II , 1994, FEBS letters.

[8]  E. Malchiodi,et al.  Activation of human platelets by immune complexes prepared with cationized human IgG , 1993 .

[9]  E. Malchiodi,et al.  Activation of human neutrophils and monocytes induced by immune complexes prepared with cationized antibodies or antigens. , 1993, Clinical Immunology and Immunopathology.

[10]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[11]  P. Isakson,et al.  Leukocytes synthesize angiotensinogen. , 1993, Hypertension.

[12]  N. Hollenberg,et al.  Quality of Life and Antihypertensive Therapy in Men -- A Comparison of Captopril with Enalapril , 1993 .

[13]  R. Alexander,et al.  Counterpoint: molecular analysis of the angiotensin II receptor. , 1992, Endocrine reviews.

[14]  M. Isturiz,et al.  Neutrophil Erythrotoxicity Induced by Phorbol Myristate Acetate: Mechanisms Involved in Neutrophil Activation , 1991, Journal of leukocyte biology.

[15]  D. Golde,et al.  Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors. , 1986, Journal of immunology.

[16]  P A Ward,et al.  Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. , 1984, The Journal of biological chemistry.

[17]  B. Dezső,et al.  Effect of angiotensin II on macrophage functions. , 1983, Immunology.

[18]  B. Dezsö,et al.  Effect of angiotensin II on the Fc receptor activity of rat macrophages. , 1981, Immunology.

[19]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[20]  M. Peach.  Renin-angiotensin system: biochemistry and mechanisms of action. , 1977, Physiological reviews.

[21]  P. Murphy.  The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.

[22]  E. Malchiodi,et al.  Activation of human platelets by immune complexes prepared with cationized human IgG. , 1993, Blood.

[23]  P. Timmermans,et al.  Pharmacology of nonpeptide angiotensin II receptor antagonists. , 1992, Annual review of pharmacology and toxicology.

[24]  A. Böyum.  Separation of leukocytes from blood and bone marrow. Introduction. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.